Valencia biotechnology company MannKind Corp. thought it had encouraging news about its experimental insulin inhaler on Tuesday. But Wall Street wasn’t buying it. For months, skeptical traders have expressed concern that the diabetes drug, if approved by the Food and Drug Administration, might end up with an FDA cancer advisory. Fears that the inhaler would never take off were still lurking Tuesday, even though MannKind said that trials of its Technosphere insulin delivery system showed no elevated cancer risk. For the full story visit www.latimes.com/business/la-fi-mannkind17-2008sep17,0,6959434.story
